Pfizer invests $150m for microbial resistance

Pfizer Australia has announced a major upgrade to its manufacturing facility in Melbourne to boost production of pharmaceuticals aiming to help address rising levels of antimicrobial resistance. Pfizer has invested $150 million to develop advanced pharmaceutical production facilities for new antimicrobial treatments tackling what is one of the biggest threats to global health. The Victorian…

BioCina and NovaCina form strategic alliance

Microbial development and contract manufacturing companies Adelaide’s BioCina and Perth’s NovaCina have announced a strategic partnership to provide integrated drug substance and drug product solutions for the pharmaceutical sector. The two companies are buy-outs from the Pfizer pharmaceutical company and share the same investor – private investment firm Bridgewest Group – and will now collaborate…

BridgeWest adds NovaCina to pharmaceutical assets

Private investment firm, Bridgewest Group has expanded its pharmaceuticals portfolio, announcing the purchase of the sterile injectable manufacturing facility of Pfizer (Perth) Pty Ltd, a subsidiary of Pfizer, Inc. The cGMP manufacturing facility, located in Bentley, Perth is a diverse sterile injectable manufacturing facility, approved to supply drug products in over 90 countries with approvals…